NCT Number: NCT00236106
Short Term Growth in Children With Atopic Dermatitis
Main objective:to assess short term growth in children with atopic dermatitis during treatment with tacrolimus 0.1% and mometasone furoate 0.1%. A singl blind randomised cross over trial including 20 children. The study consists of 5 periods: run in, treatment(1),wash out, treatment(2) and run out. Each period 14 days where the children will use tacrolimus ointment tvice daily, mometasone furoate once daily or moisturizer (in run in wash out and run out)
Looking for future studies?
Notify MeKey information
Conditions
Age range
5 year–14 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
age 5-14, atopic dermatitis, normal current growth, Tanner 1, informed consent by the parent or guardian, willing and able to comply with study procedures
Exclusion criteria
Tanner 2-5, treatment of atopic dermatitis with anti-inflammatory agent within 1 week before the first visit, current asthma or rhinoconjunctivitis that requires treatment with glucocorticoids, endocrine diseases, major surgery within 4 weeks prior to visit 1, fever >39.5 for >3 days
Treatment and study plan
mometasone furoate 0.1%
DrugPrimary outcomes
-
short term growth during treatment compared to run in
Secondary outcomes
-
U-EPX
-
U-nTX
-
skin prick test
Sponsors and collaborators
Lead sponsor
Children´s Clinic, Randers
Other
Registry information
Important dates
- Study start
- 2005
- Study completion
- 2005
- First posted
- Oct 12, 2005
- Registry last updated
- Dec 9, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Modified Huang-Lian-Jie-Du Decoction (MHLJDD) for Atopic Dermatitis in Children
NCT05613062
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hong Kong
View Trial DetailsA Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05633355
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Phoenix, Arizona, United States
View Trial DetailsA Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
NCT05899816
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Scottsdale, Arizona, United States
View Trial DetailsA Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
NCT05398445
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial Details